2025 Clinical Immunology Society Conference
2025 Clinical Immunology Society Conference
2025 Clinical Immunology Society Conference
The CGDAA hosted two events focused on advancing research and raising awareness for Chronic Granulomatous Disease (CGD).
One of the highlights was our abstract poster presentation of the groundbreaking study led by Dr. Christin Deal, MD, of UPMC Children’s Hospital of Pittsburgh and presented by Dr. Jennifer Leiding, MD, of Johns Hopkins All Children’s Hospital. This research explored post-transplant outcomes for individuals with CGD and revealed highly encouraging results. Read more.
CGDAA Featured in PIDTC Newsletter
2025 Clinical Immunology Society Conference
2025 Clinical Immunology Society Conference
The CGD Association of America's recently published article in "Clinical Immunology" regarding X-linked female carriers of CGD was featured in the November issue of Primary Immune Deficiency Treatment Consortium's (PIDTC) Newsletter.
To check out this special report and learn more about the CGDAA's partnership with the PIDTC, the top research consortium for primary immune deficiencies in North America, read more here.
Study published in Clinical Immunology
Study published in Clinical Immunology
Study published in Clinical Immunology
We are so excited to announce that our own Felicia Morton, along with CGDAA medical advisory board members Dr. Jennifer Leiding, adjunct professor John's Hopkins University and attending physician, Orlando Health Arnold Palmer Hospital for Children and Dr. Harry Malech, National Institutes of Health, Genetic Immunotherapy Section Deputy Chief, Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infections Diseases, have authored a first-of-its-kind research study regarding female carriers of X-linked CGD, entitled "The high symptom burden in female X-linked chronic granulomatous disease carriers."
The highlights of the study include:
- XL CGD female carriers are an underrecognized population
- Autoimmune and inflammatory symptoms are the most commonly reported
- An alarmingly high rate of anxiety is reported in XL-CGD female carriers
The study will be published in the November issue of “Clinical Immunology,” the top peer-review medical journal for immunology research. Download and read the study here!
We are grateful to Amgen for the their support of this initiative.
2024 IDF Conference
Study published in Clinical Immunology
Study published in Clinical Immunology
The IDF conference featured several notable presentations, sponsored by Amgen, that resonated deeply with our community. The insightful talk by Harry Malech, MD, Chief, Genetic Immunotherapy Section, National Institutes of Health, and moderated by Felicia Morton, Executive Director of the CGD Association of America, on the latest advances in CGD research and treatment was a highlight, thanks to his perspective on the new advances in stem cell transplants and gene therapy.
The conference wasn't just about learning and sharing information; it was also about building connections and creating lasting memories. To that end, our organization hosted a dinner, sponsored by Prime Medicine, which provided a platform for CGD patients and families to share their inspiring stories and experiences, contributing to Prime Medicine's mission of developing transformative therapies.